Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RARA | P10276 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.56 |
| ▸ | LPL | P06858 | 1/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11442846 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL289254 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL27414335 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL15766204 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL15174619 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL9812591 | 0.98 | RARB (0.58) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL443913 | 0.98 | RARB (0.58) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL31124111 | 0.93 | FOLH1 (0.58) | RARBPPARAPPARG | |
| SCHEMBL3387825 | 0.93 | FOLH1 (0.58) | RARBPPARAPPARG | |
| SCHEMBL9789538 | 0.91 | PPARA (0.65) | MAPTPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| CN-107922604-B | Novel formulations for pressure sensitive adhesives | 雷普索尔有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3443957-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2019-02-20 | — | — | EP | disclosed |
| US-9475750-B2 | Phenylketone carboxylate compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2016-10-25 | — | — | US | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9114118-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-20130225681-A1 | Phenylketone Carboxylate Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-29 | — | — | US | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-05-05 | — | — | US | disclosed |
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-05-05 | — | — | US | disclosed |
| WO-2009146112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | RARB 2113/4885MEN1 3382/4885ALDH1A1 467/4885 |
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | SPHK2, SPHK1, S1PR2 | RARB 4809/4885MEN1 1442/4885ALDH1A1 4650/4885 |
| US-20130225681-A1 | Phenylketone Carboxylate Compounds and Pharmaceutical Uses Thereof | BCKDK, PDK4, FAH | RARB 4770/4885MEN1 4317/4885ALDH1A1 1168/4885 |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | DCK, TOP2B, TOP2A | RARB 2113/4885MEN1 3382/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.